Aclaris Therapeutics, Inc.
ACRS
$1.57
$0.063.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 84.38% | -1,172.77% | 30.95% | 35.15% | -1,036.22% |
| Total Depreciation and Amortization | -10.49% | -20.11% | -26.03% | -0.41% | 6.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.66% | 2,225.58% | 22.59% | -36.53% | 126.04% |
| Change in Net Operating Assets | -94.67% | -103.88% | 646.96% | 48.02% | -167.85% |
| Cash from Operations | -46.08% | -140.63% | 278.54% | 40.80% | -207.87% |
| Capital Expenditure | -- | -- | -100.00% | 110.37% | 69.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 121.60% | -3,274.35% | 506.25% | -104.05% | 112.34% |
| Cash from Investing | 121.55% | -3,274.35% | 514.69% | -104.00% | 122.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 249,900.00% | -- | -- | -- |
| Repurchase of Common Stock | 17.42% | -3,230.00% | 9.09% | 80.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.37% | 338,900.00% | 300.00% | 80.00% | -212.24% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 125.07% | -193.00% | 290.80% | -222.19% | -581.74% |